Prometheus Materials’ Bio-Cement and Bio-Concrete Achieves 12x the Sound Absorption of Traditional Concrete in ASTM Testing
2.8.2023 15:00:00 EEST | Business Wire | Press release
Prometheus Materials, a leader in sustainable building materials, announced today the achievement of remarkable results in the ASTM C423 sound-absorption testing of its ground-breaking bio-cement and bio-concrete technology. The company develops revolutionary zero-carbon building solutions that provide a superior alternative to carbon-intensive portland cement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802310284/en/
Prometheus Materials' superior sound-absorption performance compared to traditional concrete (Graphic: Business Wire)
The Johns Manville Technical Center in Littleton, Colorado – a world-class research and development facility – conducted the independent testing, which found that Prometheus Materials’ bio-concrete demonstrated a Noise Reduction Coefficient (NRC) of 0.60. This NRC rating indicates 60% sound absorption – twelve times that of traditional concrete.
Prometheus Materials’ initial pre-cast bio-concrete product line includes masonry units, segmented modular block and acoustic panels – where this exceptional sound-absorption characteristic will be an essential feature – as well as paving stones and grass pavers. These products are currently available strictly for select projects, with commercial availability slated for the first half of 2024.
Such unrivaled sound absorption is a cost-saving, environment-enhancing boon for various sectors. In settings where noise can be damaging or distracting, builders are often forced to rely on secondary products to achieve some measure of noise reduction. Beyond the added expense, these materials can sometimes have negative effects – including health risks. However, with Prometheus Materials’ bio-cement and bio-concrete products, such facilities can incorporate sound-absorption capabilities without additional cost, safety concerns or other drawbacks. Residential, commercial and institutional buildings, amphitheaters, music studios, highway barriers – and a vast array of other end-uses – will all benefit from this exceptional noise-reduction capability, while concurrently reducing their carbon footprint.
“Our latest ASTM testing results embody our commitment to innovative design,” said Loren Burnett, President, CEO & Co-founder of Prometheus Materials. “We’ve developed a novel material that provides a zero-carbon alternative to traditional concrete while delivering additional performance benefits and applications. We’re proud to pave the way toward a more technologically advanced and environmentally responsible future for the construction industry.”
Vishaan Chakrabarti, FAIA FRAIC – renowned architect, academic and business leader with focus on sustainable design; Founder and Creative Director of Practice for Architecture & Urbanism (PAU); and member of Prometheus Materials’ Board of Directors – was equally inspired. “Test results like these prove that Prometheus Materials has developed far more than zero-carbon concrete – which by itself is an enormous accomplishment,” he said. “With this level of sound absorption, as well as other characteristics currently being tested, it's clear that this material will offer a suite of products based on entirely redefined ideas of what concrete can be and do.”
Prometheus Materials continues to lead the charge in sustainability and innovation within the building materials sector. With these ASTM C423 sound-absorption results joining its previously secured ASTM C129 and C90 certifications – plus other features of its bio-cement and bio-concrete that are comparable or superior to traditional concrete – the company is poised to drive the construction industry toward a more cutting-edge and sustainable future.
About Prometheus Materials
Prometheus Materials provides sustainable building materials that accelerate the world’s transition to a carbon-negative future. Inspired by biological processes found in nature, the company’s process uses microalgae to produce a bio-cement that offers an alternative to carbon-intensive portland cement. When mixed with aggregate, this bio-cement forms a zero-carbon bio-concrete with mechanical, physical and thermal properties that rival those of portland cement-based concrete. Learn more about how the company enables the decarbonization of the construction industry at prometheusmaterials.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230802310284/en/
Contact information
Liz Crumpacker
Antenna Group
prometheus@antennagroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
